Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia

Conference contribution


Publication Details

Author(s): Chaturvedi A, Cruz MMA, Goparaju R, Gabdoulline R, Schottmann R, Goerlich K, Kloos A, Thol F, Geffers R, Mougiakakos D, Carmeliet P, Ganser A, Heuser M
Publisher: AMER SOC HEMATOLOGY
Publishing place: WASHINGTON
Publication year: 2018
Conference Proceedings Title: BLOOD
ISSN: 0006-4971


FAU Authors / FAU Editors

Mougiakakos, Dimitrios
Professur für Hämatologie/Onkologie mit dem Schwerpunkt Tumorimmunologie


External institutions with authors

Flanders Institute for Biotechnology / Vlaams Instituut voor Biotechnologie (VIB)
Helmholtz-Zentrum für Infektionsforschung (HZI)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School


How to cite

APA:
Chaturvedi, A., Cruz, M.M.A., Goparaju, R., Gabdoulline, R., Schottmann, R., Goerlich, K.,... Heuser, M. (2018). Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia. In BLOOD. San Diego, CA, US: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:
Chaturvedi, Anuhar, et al. "Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia." Proceedings of the 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA WASHINGTON: AMER SOC HEMATOLOGY, 2018.

BibTeX: 

Last updated on 2019-11-03 at 12:08